Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with a high metastatic potential. Treatment with chemotherapy can produce high response rates, but potential relapse rates are ...

"This is the largest retrospective study to assess and demonstrate that immune-related toxicity is positively associated with improved clinical outcomes in patients with ES-SCLC [extensive-stage ...

Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

SCLC patients, particularly with high tumor burden, face significant ATLS risk, despite typically low overall risk in solid tumors. Early recognition and aggressive intervention are crucial, yet ...